New Drug Rules On Licensing, Trials, Surveillance Edge Closer In Singapore
This article was originally published in SRA
Executive Summary
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.
You may also be interested in...
Singapore: Less Than Three Months Left For Companies To Prepare For New Pharma Rules
Singapore's efforts to consolidate and streamline the regulatory control of all health products under a single legislation has resulted in the fine-tuning of certain regulatory provisions that drug companies should be aware of.
Migraine & Hepatitis B Prevention Products Among New EU Filings
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Another EU Filing Targets Burgeoning NMOSD Market
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: